-

Butterfly Network to Participate in TD Cowen’s Medical Devices Emerging Growth Call Series on June 18, 2026

Webcast occurring at 12:00pm ET on Thursday, June 18, 2026.

NEW YORK & BURLINGTON, Mass.--(BUSINESS WIRE)--Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”), today announced that it will participate in the TD Cowen Medical Devices Emerging Growth Call Series at 12:00pm ET on June 18, 2026. Joseph DeVivo, President, Chief Executive Officer & Chairman; John Doherty, EVP, Chief Financial Officer and David Horsley, SVP, Innovation, will take part in the discussion.

To register or access the audio-only webcast, visit the Events & Presentations section of the Butterfly investor website (https://ir.butterflynetwork.com/events-and-presentations).

About Butterfly Network

Butterfly Network, Inc. (NYSE: BFLY) is driving a digital revolution in ultrasound imaging and sensing with its proprietary Ultrasound-on-Chip™ semiconductor technology and software solutions. Butterfly first proved its technology in the point-of-care ultrasound market – commercializing the world’s first single-probe, whole-body portable ultrasound device, which is now on its best-selling, third-generation: Butterfly iQ3™. The Company combines its advanced hardware with cloud software and AI, an enterprise workflow solution (Compass AI™) and other offerings to drive adoption of affordable, accessible ultrasound. Butterfly also enables third-party development of imaging AI apps through Butterfly Garden™, its software development kit and AI marketplace.

In addition to its medical imaging products, Butterfly Embedded™ is the Company’s Ultrasound-on-Chip™ licensing and co-development business initiative designed to enable a new wave of ultrasound-enabled technologies across non-competitive healthcare markets and beyond. Through Butterfly Embedded™, partners can build and scale novel ultrasound applications powered by Butterfly’s proprietary semiconductor chip and software platform.

Butterfly’s innovations have been recognized by Prix Galien USA, Fierce 50, TIME’s Best Inventions and Fast Company’s World Changing Ideas, among other achievements. To learn more, visit: www.butterflynetwork.com

Contacts

Investors:
John Doherty
Chief Financial Officer
investors@butterflynetinc.com

Industry:

Butterfly Network, Inc.

NYSE:BFLY
Release Versions
English
$Cashtags
$BFLY
Hashtags
#POCUS
#healthcare
#semiconductors
#ultrasound

Contacts

Investors:
John Doherty
Chief Financial Officer
investors@butterflynetinc.com

Social Media Profiles
Facebook
LinkedIn
Twitter
More News From Butterfly Network, Inc.

Butterfly Network Provides Commentary on Midjourney Medical’s Full Body Ultrasound Scanner Announcement

BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE)--Butterfly Network, Inc. (“Butterfly”) (NYSE: BFLY), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, today provided commentary following Midjourney's public announcement of Midjourney Medical and The Midjourney Scanner: a full-body tomographic imaging machine. The current scanner prototype incorporates 40 Butterfly Ultrasound-on-Chip™ imaging modules per system, licensed under a co-development agre...

Butterfly Network to Participate in the William Blair 46th Annual Growth Stock Conference

NEW YORK & BURLINGTON, Mass.--(BUSINESS WIRE)--Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”), today announced that the company will participate at the William Blair 46th Annual Growth Stock Conference. Joseph DeVivo, President, Chief Executive Officer & Chairman and John Doherty, EVP, Chief Financial Officer will participate in a presentation breakout session at 8:40 AM CT on June 4, 2026, and host one-on-one investor meetings throughout the day. A webcast of the presentation will be a...

Butterfly Network Appoints Caroll H. Neubauer to Board of Directors

NEW YORK & BURLINGTON, Mass.--(BUSINESS WIRE)--Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, today announced the appointment of Caroll H. Neubauer to its Board of Directors, effective May 18, 2026. Mr. Neubauer will serve on the Board’s Compensation Committee and Technology Committee. Mr. Neubauer has achieved a distinguished career spanning three decades with B. Braun, including serving fo...
Back to Newsroom